Ligence, a leader in echocardiography automation technology, has attracted €3 million in seed funding led by venture capital firm Simpact Ventures. This funding will drive Ligence’s expansion efforts as the company prepares for FDA clearance in early 2025, opening new opportunities to make high-quality cardiac diagnostics more accessible worldwide.
Advancing Echocardiography with Ligence Heart
Ligence Heart reshapes the echocardiography workflow by automating measurements and reporting, resulting in faster, more accurate results. In the study conducted in 2020, Ligence remarkably showed that the diagnostic accuracy is non-inferior to that of experienced cardiologists—an impressive achievement in a field where variability is a common challenge. By ensuring consistent measurements, Ligence Heart provides healthcare providers with reliable data for confident decision-making, especially in follow-up care.
Dr. René Nkoulou, a cardiologist from Switzerland, highlights the platform’s efficiency: “I am saving 15 minutes per every patient.” This significant time-saving enables healthcare providers to either increase patient throughput or spend more quality time with each patient, ultimately enhancing the standard of care.
Transparent, Integrable, and Ready for Expansion
Ligence is built on a state-of-the-art, highly integrable software architecture, seamlessly connecting with PACS and other hospital systems. Unlike black-box solutions that only indicate potential conditions, Ligence provides transparent, guideline-based measurements aligned with ASE and ESC standards, empowering clinicians with full visibility into each patient’s cardiac health.
In its commitment to advancing cardiac care, Ligence is conducting research with prestigious institutions, including Dr Haotian Gu, leader of the Gu Laboratory at King’s College London, as well as leading scientific clinical centers in the United States. This collaboration not only strengthens Ligence’s solution but also reinforces its credibility among top clinical researchers worldwide.
Looking forward, Ligence anticipates receiving FDA clearance by early 2025, opening doors to expand its impact in the U.S. market. With its robust accuracy, interoperability, and patient-centered design, Ligence is poised to lead the future of cardiac diagnostics. Already compatible with major hospital IT systems and PACS platforms, Ligence is equipped to meet the growing demands of healthcare providers and address the rising global need for efficient cardiovascular care.
